$AYTU Aytu BioScience Presents New Research Findings for Natesto(R) at the Endocrine Society's 100th Annual Meeting
Post-hoc Data Analysis Demonstrates Natesto's Restoration of Normal Testosterone Levels in Hypogonadal Men While Maintaining Normal Levels of Estradiol (E2) and Dihydrotestosterone (DHT), Which Are Frequently Altered in Men Treated With Testosterone Replacement Therapy
ENGLEWOOD, CO / ACCESSWIRE / March 20, 2018 / Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that it presented a moderated poster presentation illustrating safety benefits of Natesto therapy restoring normal testosterone levels to hypogonadal men, while maintaining normal, but not high levels of testosterone metabolites estradiol (E2) and dihydrotestosterone (DHT).
The presentation took place on March 18, 2018 at ENDO 2018, the Endocrine Society's annual meeting and the world's premier event for presenting and obtaining the latest in endocrine science and medicine.
The presentation details are as follows:
Title: Intranasal Testosterone Therapy (TTh) Produces Normal, Not High, Estradiol (E2) And Dihydrotestosterone (DHT) Levels in Hypogonadal Men
Poster Number: SUN-391
Session: Steroid Biology and Action
Presenter: Alan D. Rogol, MD, University of Virginia, Endocrinology
Conclusion: Treatment with Natesto® restored serum testosterone levels to normal levels in hypogonadal men without excursions above the normal range. 24hr Cavg of both DHT and E2 also returned to normal ranges and illustrates, that with Natesto® treatment, it is unlikely to produce potential adverse events considered secondary to high DHT and E2.
Josh Disbrow, Chief Executive Officer of Aytu BioScience, stated, ''The body of clinical evidence continues to build with Natesto, and this important post hoc analysis from the Natesto Clinical Study Report demonstrates the unique profile of Natesto as it relates to maintaining normal levels of key testosterone metabolites. Both DHT and estradiol levels are frequently altered in men receiving testosterone replacement therapy and can lead to various unwanted side effects, so this analysis identifies a unique aspect to Natesto's favorable safety profile and may offer distinct benefits to men who are treated with Natesto.''
Selection of the abstracts for publication in the press program does not imply endorsement of Natesto® by the Endocrine Society.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. The Company currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or ''Low T''
and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging. Additionally, Aytu is developing MiOXSYS®, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS® is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared, Australian TGA approved product, and Aytu is planning U.S.-based clinical trials in pursuit of 510k medical device clearance by the FDA. Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within growing markets.
For more information visit www.aytubio.com. Aytu also now wholly-owns its subsidiary Aytu Women's Health (formerly Nuelle, Inc.), a personal health and wellness company focused on women's sexual wellbeing and intimacy. Aytu Women's Health markets Fiera, a personal care product for women that is scientifically proven to enhance physical arousal and sexual desire. Fiera is a consumer product and is not intended to treat, mitigate, or cure any disease or medical condition. For more information about the Fiera personal care product visit fiera.com.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words ''anticipate,'' ''believe,'' ''estimate,'' ''upcoming,'' ''plan,'' ''target'', ''intend'' and ''expect'' and similar expressions, as they relate to Aytu BioScience, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Contact for Investors:
James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com
SOURCE: Aytu BioScience, Inc.
Post-hoc Data Analysis Demonstrates Natesto's Restoration of Normal Testosterone Levels in Hypogonadal Men While Maintaining Normal Levels of Estradiol (E2) and Dihydrotestosterone (DHT), Which Are Frequently Altered in Men Treated With Testosterone Replacement Therapy
ENGLEWOOD, CO / ACCESSWIRE / March 20, 2018 / Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that it presented a moderated poster presentation illustrating safety benefits of Natesto therapy restoring normal testosterone levels to hypogonadal men, while maintaining normal, but not high levels of testosterone metabolites estradiol (E2) and dihydrotestosterone (DHT).
The presentation took place on March 18, 2018 at ENDO 2018, the Endocrine Society's annual meeting and the world's premier event for presenting and obtaining the latest in endocrine science and medicine.
The presentation details are as follows:
Title: Intranasal Testosterone Therapy (TTh) Produces Normal, Not High, Estradiol (E2) And Dihydrotestosterone (DHT) Levels in Hypogonadal Men
Poster Number: SUN-391
Session: Steroid Biology and Action
Presenter: Alan D. Rogol, MD, University of Virginia, Endocrinology
Conclusion: Treatment with Natesto® restored serum testosterone levels to normal levels in hypogonadal men without excursions above the normal range. 24hr Cavg of both DHT and E2 also returned to normal ranges and illustrates, that with Natesto® treatment, it is unlikely to produce potential adverse events considered secondary to high DHT and E2.
Josh Disbrow, Chief Executive Officer of Aytu BioScience, stated, ''The body of clinical evidence continues to build with Natesto, and this important post hoc analysis from the Natesto Clinical Study Report demonstrates the unique profile of Natesto as it relates to maintaining normal levels of key testosterone metabolites. Both DHT and estradiol levels are frequently altered in men receiving testosterone replacement therapy and can lead to various unwanted side effects, so this analysis identifies a unique aspect to Natesto's favorable safety profile and may offer distinct benefits to men who are treated with Natesto.''
Selection of the abstracts for publication in the press program does not imply endorsement of Natesto® by the Endocrine Society.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. The Company currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or ''Low T''
and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging. Additionally, Aytu is developing MiOXSYS®, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS® is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared, Australian TGA approved product, and Aytu is planning U.S.-based clinical trials in pursuit of 510k medical device clearance by the FDA. Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within growing markets. For more information visit www.aytubio.com. Aytu also now wholly-owns its subsidiary Aytu Women's Health (formerly Nuelle, Inc.), a personal health and wellness company focused on women's sexual wellbeing and intimacy. Aytu Women's Health markets Fiera, a personal care product for women that is scientifically proven to enhance physical arousal and sexual desire. Fiera is a consumer product and is not intended to treat, mitigate, or cure any disease or medical condition. For more information about the Fiera personal care product visit fiera.com.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words ''anticipate,'' ''believe,'' ''estimate,'' ''upcoming,'' ''plan,'' ''target'', ''intend'' and ''expect'' and similar expressions, as they relate to Aytu BioScience, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Contact for Investors:
James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com
SOURCE: Aytu BioScience, Inc.
Engineer by trade & Swing Trader at Heart!
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
